Lidocaine Patches for Attenuating the Pain of Venipuncture Intravenous Cannulation
NCT ID: NCT02061475
Last Updated: 2014-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
240 participants
INTERVENTIONAL
2014-04-30
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lidocaine Patches
Lidocaine Patches
Placebo Patches
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidocaine Patches
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age from 18 to 65 years old
* Patients who need intravenous cannulation before surgery
* ASA class I-II and selected patients
Exclusion Criteria
* Allergic skin(allergic to past agent or other topical used medicine)
* Skin injured or inflection exist in the local site to patch
* Sensation disturbed in any limb
* Severe liver and kidney original disease:blood Aspertate aminotransferase and Alanine transaminase increased 1.5 times more than normal concentration; blood creatinine is higher than the normal range.
* Hemoglobin \<80g/L
* ECG is significantly abnormal
* pregnant or possible pregnant or breastfeeding woman
* Patient who has consciousness disturbance can not make credible dialog with investigator.
* Those who are using other medicine may affect the evaluation of present patch
* Those who have participated in other clinical trail in the past three months
* Those excluded by investigator believed other reasons.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nitto Denko Corporation
INDUSTRY
Giant Med-Pharma Services Inc.
INDUSTRY
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diansan Su, Dr.
Role: PRINCIPAL_INVESTIGATOR
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Xiangrui Wang, Dr.
Role: STUDY_CHAIR
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Yanhua Zhao, Dr.
Role: PRINCIPAL_INVESTIGATOR
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, Beijing Municipality, China
Guanzhou First people's Hospital
Guangzhou, Guangdong, China
Xiangya Hospital Central South University
Changhai, Hunan, China
The First Affiliate Hospital of Soochow University
Suzhou, Jiangsu, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Zhongshan Hospital Affiliated to Shanghai Fudan University
Shanghai, Shanghai Municipality, China
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xinmin Wu, Dr.
Role: primary
Lixin Xu, Dr.
Role: primary
Qulian Guo, Dr.
Role: primary
Jianping Yang, Dr.
Role: primary
Xiuying Wu, Dr.
Role: primary
Zhanggang Xue, Dr.
Role: primary
Diansan Su, Dr.
Role: primary
Shitong Li, Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LCLDKY-13115
Identifier Type: -
Identifier Source: org_study_id